MARKET

MRTX

MRTX

Mirati
NASDAQ

Real-time Quotes | Nasdaq Last Sale

150.54
+2.91
+1.97%
After Hours: 150.54 0 0.00% 16:47 05/11 EDT
OPEN
144.00
PREV CLOSE
147.63
HIGH
154.38
LOW
143.42
VOLUME
1.22M
TURNOVER
--
52 WEEK HIGH
249.42
52 WEEK LOW
91.90
MARKET CAP
7.74B
P/E (TTM)
-17.5057
1D
5D
1M
3M
1Y
5Y
Mirati Therapeutics (MRTX) Received its Third Buy in a Row
After H.C. Wainwright and J.P. Morgan gave Mirati Therapeutics (NASDAQ: MRTX) a Buy rating last month, the company received another Buy, this time from
SmarterAnalyst · 20h ago
At Home, Beyond Meat, Lyft, Raytheon and More Monday Afternoon Analyst Calls
247WallSt.com · 1d ago
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2021
 
Benzinga · 1d ago
10 Biggest Price Target Changes For Monday
BMO Capital boosted The Middleby Corporation (NASDAQ: MIDD) price target from $225 to $250. Middleby shares rose 1.9% to close at $182.83 on Friday.
Benzinga · 1d ago
Jefferies Upgrades Mirati Therapeutics to Buy, Lowers Price Target to $196
Jefferies analyst Maury Raycroft upgrades Mirati Therapeutics (NASDAQ:MRTX) from Hold to Buy and lowers the price target from $208 to $196.
Benzinga · 1d ago
DJ Mirati Therapeutics Price Target Cut to $196.00/Share From $208.00 by Jefferies
Dow Jones · 1d ago
DJ Mirati Therapeutics Raised to Buy From Hold by Jefferies
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Mirati Therapeutics, Lowers Price Target to $251
HC Wainwright & Co. analyst Edward White maintains Mirati Therapeutics (NASDAQ:MRTX) with a Buy and lowers the price target from $255 to $251.
Benzinga · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRTX. Analyze the recent business situations of Mirati through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRTX stock price target is 237.11 with a high estimate of 300.00 and a low estimate of 174.00.
EPS
Institutional Holdings
Institutions: 360
Institutional Holdings: 61.61M
% Owned: 120.02%
Shares Outstanding: 51.44M
TypeInstitutionsShares
Increased
103
6.25M
New
82
1.76M
Decreased
79
3.44M
Sold Out
19
108.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Director
Faheem Hasnain
Chairman/Director
faheem Hasnain
President/Chief Executive Officer/Director
Charles Baum
Chief Operating Officer/Executive Vice President
Daniel Faga
Executive Vice President/Chief Scientific Officer
James Christensen
Executive Vice President
Benjamin Hickey
Independent Director
Bruce Carter
Senior Vice President/Chief Accounting Officer
Vickie Reed
Independent Director
Julie Cherrington
Vice President/Director of Human Resources
Jenny Gizzi
Independent Director
Aaron Davis
Independent Director
Henry Fuchs
Independent Director
Michael Grey
Independent Director
Craig Johnson
Independent Director
Maya Martinez-Davis
Independent Director
Shalini Sharp
No Data
  • All
  • Financials
  • Insiders
More
About MRTX
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit KRAS G12C mutations which are present in non-small cell lung cancer (NSCLC) adenocarcinoma patients, colorectal cancer (CRC) patients, pancreatic cancer patients, as well as several other difficult-to-treat cancers. Sitravatinib is a spectrum-selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.

Webull offers kinds of Mirati Therapeutics Inc stock information, including NASDAQ:MRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRTX stock methods without spending real money on the virtual paper trading platform.